Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of June 2026, specifically dated June 1, 2026. The report serves to disseminate a press release regarding clinical trial results presented at the 2026 ASCO Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical developments rather than financial performance.
Material Changes
The primary material event is the announcement of strong overall survival results from the Alpha DaRT® pancreatic cancer studies. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the positive clinical outcomes of the Alpha DaRT® studies. The filing includes standard legal disclaimers stating that the information is furnished and not "filed" under Section 18 of the Exchange Act, limiting liability. No specific financial guidance, risk factors, or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the full details of the "strong overall survival results" in the attached Exhibit 99.1 press release.
- Confirm the specific statistical significance and patient cohort size for the Alpha DaRT® pancreatic cancer studies.
- Review the Company's most recent Form 20-F for actual financial metrics, as this 6-K contains none.
- Monitor subsequent regulatory filings for any updates on the commercialization timeline following these clinical results.